The BCG Vaccine for COVID-19: First Verdict and Future Directions.
The BCG Vaccine for COVID-19: First Verdict and Future Directions.
复制标题
DOI：
10.3389/fimmu.2021.632478
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Ochando J
中科院分区：
文献类型：
--
作者：
Gonzalez-Perez M;Sanchez-Tarjuelo R;Shor B;Nistal-Villan E;Ochando J
尽管针对严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）的疫苗开发迅速，但仍需要几个月的时间才能获得足够的剂量和适当的基础设施，为世界上相当一部分人口接种疫苗。在此期间，卡介苗（BCG）的可获得性可能会减轻一些国家的大流行影响，而BCG疫苗在临床疫苗接种方面具有显著优势和灵活性。BCG疫苗接种是一种极具成本效益的结核病干预措施，许多低收入和中低收入国家可能拥有足够熟悉传统结核病疫苗的基础设施和卫生保健人员，以全面开展基于BCG的新型COVID-19疫苗的管理工作。这表明BCG有潜力克服未来在卫生系统脆弱以及这种新型冠状病毒的影响可能是灾难性的国家推广疫苗的障碍。许多研究报告了卡介苗对非结核病相关疾病的交叉保护作用。从机制上讲，BCG疫苗的这种交叉保护作用可以部分地通过训练的免疫来解释，训练的免疫是最近发现的先天免疫记忆程序，其特征在于巨噬细胞的非永久性表观遗传重编程，其导致增加的炎性细胞因子产生并因此产生有效的免疫应答。在这篇综述中，我们总结了最近的工作，突出了BCG在治疗呼吸道感染性疾病和正在进行的SARS-CoV-2临床试验的潜在用途。在没有其他特定预防工具可用的情况下，BCG疫苗可用作潜在的佐剂，以减少SARS-CoV-2感染的疾病和/或减轻并发呼吸道感染的影响。
Despite of the rapid development of the vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses and the proper infrastructure to vaccinate a good proportion of the world population. In this interim, the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the pandemic impact in some countries and the BCG vaccine offers significant advantages and flexibility in the way clinical vaccines are administered. BCG vaccination is a highly cost-effective intervention against tuberculosis (TB) and many low-and lower-middle-income countries would likely have the infrastructure, and health care personnel sufficiently familiar with the conventional TB vaccine to mount full-scale efforts to administer novel BCG-based vaccine for COVID-19. This suggests the potential for BCG to overcome future barriers to vaccine roll-out in the countries where health systems are fragile and where the effects of this new coronavirus could be catastrophic. Many studies have reported cross-protective effects of the BCG vaccine toward non-tuberculosis related diseases. Mechanistically, this cross-protective effect of the BCG vaccine can be explained, in part, by trained immunity, a recently discovered program of innate immune memory, which is characterized by non-permanent epigenetic reprogramming of macrophages that leads to increased inflammatory cytokine production and consequently potent immune responses. In this review, we summarize recent work highlighting the potential use of BCG for the treatment respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials. In situations where no other specific prophylactic tools are available, the BCG vaccine could be used as a potential adjuvant, to decrease sickness of SARS-CoV-2 infection and/or to mitigate the effects of concurrent respiratory infections.
登录
查看更多内容
DOI：
10.1016/j.urolonc.2008.12.017
发表时间：
2010-09-01
影响因子：
2.7
作者：
Andrade, Priscila M.;Chade, Daher C.;Srougi, Miguel
通讯作者：
Srougi, Miguel
影响因子：
5.5
作者：
Dennehy, Maureen;Bourn, William;Williamson, Anna-Lise
通讯作者：
Williamson, Anna-Lise
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1016/j.clim.2014.10.005
发表时间：
2014-12
期刊：
Clinical immunology (Orlando, Fla.)
影响因子：
--
作者：
Kleinnijenhuis J;Quintin J;Preijers F;Joosten LA;Jacobs C;Xavier RJ;van der Meer JW;van Crevel R;Netea MG
通讯作者：
Netea MG
影响因子：
5.4
作者：
Channappanavar, Rudragouda;Fett, Craig;Perlman, Stanley
通讯作者：
Perlman, Stanley